Oncolytics Biotech, Inc. (ONCY)
Nasdaq: ONCY · Pharmaceutical Preparations · Calgary · filing with the SEC since 2002
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 30, 2026 | Mar 7, 2025 | Mar 12, 2024 |
| Research and development | 13,314 | 15,443 | · |
| General and administrative | 15,411 | 10,099 | · |
| Total operating expenses | 28,725 | 25,542 | · |
| Operating income | -28,725 | -25,542 | · |
| Interest and investment income | 386 | 975 | · |
| Other income (expense), net | 45 | 2,843 | · |
| Income before income taxes | -28,680 | -22,699 | · |
| Income tax expense | 79 | 95 | · |
| Net income | -28,759 | -22,794 | · |
| Earnings per share, basic | -0.30 | -0.30 | · |
| Earnings per share, diluted | -0.30 | -0.30 | · |
| Weighted average shares, basic | 95,857,147 | 76,482,914 | · |
| Weighted average shares, diluted | 95,857,147 | 76,482,914 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding